Related Experiment Video
Updated: May 12, 2025
Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
Published on: July 25, 2020
Phase II Study of Pexidartinib Plus Sirolimus in Unresectable Malignant Peripheral Nerve Sheath Tumors Identifies M2
Gulam A Manji1,2, Liam J Stanton1, Angela C Hirbe3
1Columbia University Irving Medical Center, New York, NY.
Purpose:
To evaluate the preliminary efficacy and safety of the combination of pexidartinib, an inhibitor of colony-stimulating factor-1 receptor (CSF1R), and sirolimus, a mammalian target of rapamycin inhibitor, to target infiltrating M2 macrophages in malignant peripheral nerve sheath tumors (MPNSTs).
Patients And Methods:
This investigator-initiated, phase II, multicenter, single-arm trial enrolled patients with unresectable MPNSTs. Patients were treated with pexidartinib 1000 mg and sirolimus 2 mg orally daily. The primary end point was progression-free survival (PFS). Secondary end points included objective response, safety profile, and overall survival (OS). Pretreatment and on-treatment tumor biopsies were obtained to evaluate changes in the tumor microenvironment (TME) using multiplex immunofluorescence and differential transcriptional profiling.
Results:
Fifteen patients with MPNSTs were enrolled and 14 initiated therapy. Eight had neurofibromatosis type 1, five were sporadic, and one was undetermined. Although the target sample size was 25, because of the lower-than-expected accrual during the COVID-19 pandemic, enrollment was halted on April 12, 2023. The median PFS and median OS were 6 weeks (95% CI, 6 to 19.1) and 17.9 weeks (95% CI, 13.7 to not applicable), respectively. One patient achieved confirmed stable disease. Three patients experienced PFS ≥12 weeks. Grade 3 treatment-related toxicities (rash and leukopenia) occurred in four (28.6%) patients. Although the study did not meet its primary end point, correlative analysis demonstrated that four of the five long-term survivors had an immune-rich pretreatment TME, three of whom had a reduction in M2-tumor-associated macrophage signal with treatment.
Conclusion:
Further studies of combination of pexidartinib and sirolimus and/or immunotherapy should be performed in the subset of patients with advanced MPNST with an immune-rich TME.
Insights
This study evaluated pexidartinib and sirolimus for malignant peripheral nerve sheath tumors (MPNSTs). The combination therapy showed limited efficacy but suggested potential in patients with an immune-rich tumor microenvironment (TME).
Area of Science:
- Oncology
- Immunology
- Pharmacology
Background:
- Malignant peripheral nerve sheath tumors (MPNSTs) are aggressive sarcomas with limited treatment options.
- M2 macrophages in the tumor microenvironment (TME) are implicated in MPNST progression.
- Targeting CSF1R and mTOR pathways may modulate the TME and inhibit tumor growth.
Purpose of the Study:
- To assess the preliminary efficacy and safety of combining pexidartinib (CSF1R inhibitor) and sirolimus (mTOR inhibitor) in MPNST patients.
- To evaluate the impact of this combination therapy on M2 macrophages within the TME.
- To explore potential biomarkers for treatment response.
Main Methods:
- Phase II, single-arm, multicenter trial of pexidartinib and sirolimus in unresectable MPNSTs.
- Primary endpoint: progression-free survival (PFS). Secondary endpoints: objective response, safety, overall survival (OS).
- Tumor biopsies analyzed using multiplex immunofluorescence and transcriptional profiling to assess TME changes.
Main Results:
- Fifteen patients enrolled; 14 received treatment. Median PFS was 6 weeks; median OS was 17.9 weeks.
- One patient achieved stable disease; three had PFS ≥12 weeks.
- Grade 3 toxicities (rash, leukopenia) occurred in 28.6% of patients. Correlative analysis suggested a reduction in M2 macrophages in long-term survivors with an immune-rich TME.
Conclusions:
- The combination of pexidartinib and sirolimus did not meet the primary endpoint for MPNSTs.
- Further investigation in patients with an immune-rich TME, potentially with immunotherapy, is warranted.
- This approach may hold promise for a specific subset of advanced MPNST patients.
